Orthofix Medical has announced the limited commercial release and first patient implant of its Virtuos Lyograft.

Virtuos Lyograft is a first-of-its-kind shelf-stable and complete autograft substitute that has been developed for spine and orthopaedic procedures.

MTF Biologics prepares the allograft using a proprietary process that maintains all the biologic components necessary for bone healing in the graft.

Virtuos provides hospitals with significant logistical and economic benefits, along with enhanced storage, shipping and operating room efficiency.

Orthofix stated that Virtuos is delivered in a ready-to-use, moldable state at room temperature.

The device can be delivered and stored at room temperature, eliminating the need for large amounts of dry ice, Styrofoam containers and freezer storage.

This enables flexible shipping choices and reduced packaging, with the aim of lowering carbon emissions.

Orthofix Global Spine president Kevin Kenny said: “The Virtuos Lyograft, provided through our exclusive partnership with MTF Biologics, is at the forefront of allograft technology.

“Processed through a proprietary preservation method, Virtuos provides the best of both worlds.

“It delivers a high-quality shelf-stable bone graft with the clinical performance and superior handling that clinicians desire, as well as streamlined logistics for storage and preparation for the hospital.”

The company stated that Virtuos Lyograft is a complementary addition to its broad line of biologics offered through its collaboration with MTF Biologics.

The line includes the FiberFuse Strip allografts, Legacy DBM, Trinity Evolution, Trinity Elite, FiberFuse Advanced and AlloQuent structural allograft.

Orthofix also markets and sells the Opus osteoconductive matrix, Opus BA bioactive bone graft, O-Genesis graft delivery system and Opus Mg Set bone void filler.

In February, the company introduced Opus BA, a synthetic bioactive bone graft solution developed for cervical and lumbar spine fusion procedures.